Effect of spirulina on risk of hospitalization and death among high-risk patients with COVID-19: results from the TOGETHER trial

Journal of Alternative and Complementary Medicine•2024

Authors

G Reis, EASM Silva, DCM Silva, LJ Thabane, AC Ferreira, VEG de Souza-Campos, APM Almeida, AM Nogueira, EDS Callegari, ADF de Figueiredo-Neto, JI Forrest, JH Park, CS Wiens, CM Guo, K Thorlund, EJ Mills

COVID-19

Abstract

Background: Spirulina, a blue-green algae with immunomodulatory properties, has been proposed as a potential treatment for COVID-19. We evaluated the efficacy of spirulina in preventing hospitalization among high-risk outpatients with COVID-19 in the TOGETHER trial.

Read Full Paper

Related Publications

Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial

The Lancet Global Health • 2022

The Lancet

COVID-19

Effect of early treatment with ivermectin among patients with Covid-19

New England Journal of Medicine • 2022

COVID-19

Ivermectin

A real-time dashboard of clinical trials for COVID-19

The Lancet Digital Health • 2020

The Lancet

COVID-19